Shimizu Y, Zhao S, Yasui H, Nishijima KI, Matsumoto H, Shiga T, Tamaki N, Ogawa M, Kuge Y. A Novel PET Probe “[18F]DiFA” Accumulates in Hypoxic Region via Glutathione Conjugation Following Reductive Metabolism. Molecular Imaging and Biology. 201902; 21(1):122-129.
Murata T, Aikawa M, Saito M, Ukon N, Komori Y, Haba H, Takács S. Production cross sections of Mo, Nb and Zr radioisotopes from α-induced reaction on natZr. Applied Radiation and Isotopes. 201902; 144:47-53.
Kobayashi M, Kato T, Washiyama K, Ihara M, Mizutani A, Nishi K, Flores LG 2nd, Nishii R, Kawai K. The pharmacological properties of 3-arm or 4-arm DOTA constructs for conjugation to α-melanocyte-stimulating hormone analogues for melanoma imaging. PLOS ONE. 201903; 14(3):e0213397.
Nakata N, Kiriu M, Okumura Y, Zhao S, Nishijima KI, Shiga T, Tamaki N, Kuge Y, Matsumoto H. Comparative evaluation of [18F]DiFA and its analogs as novel hypoxia positron emission tomography and [18F]FMISO as the standard. Nuclear Medicine and Biology. 201903; 70:39-45.
Aoki M, Odani A, Ogawa K. Development of radiolabeled bis(zinc(II)-dipicolylamine) complexes for cell death imaging. Annals of Nuclear Medicine. 201905; 33(5):317-325.
Zhao S, Yu W, Ukon N, Tan C, Nishijima KI, Shimizu Y, Higashikawa K, Shiga T, Yamashita H, Tamaki N, Kuge Y. Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models. EJNMMI Research. 201906; 9(1):51.
Manabe O, Kroenke M, Aikawa T, Murayama A, Naya M, Masuda A, Oyama-Manabe N, Hirata K, Watanabe S, Shiga T, Katoh C, Tamaki N. Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake. Journal of Nuclear Cardiology. 201906; 26(3):909-918.
Watanabe S, Shiga T, Hirata K, Magota K, Okamoto S, Toyonaga T, Higashikawa K, Yasui H, Kobayashi J, Nishijima KI, Iseki K, Matsumoto H, Kuge Y, Tamaki N. Biodistribution and radiation dosimetry of the novel hypoxia PET probe [18F]DiFA and comparison with [18F]FMISO. EJNMMI Research. 201907; 9(1):60.
Sudo H, Tsuji AB, Sugyo A, Nagatsu K, Minegishi K, Ishioka NS, Ito H, Yoshinaga K, Higashi T. Preclinical evaluation of the acute radiotoxicity of the α-emitting molecular-targeted therapeutic agent 211At-MABG for the treatment of malignant pheochromocytoma in normal mice. Translational Oncology. 201907; 12(7):879-888.
Inomata T, Watanuki S, Odagiri H, Nambu T, Karakatsanis NA, Ito H, Watabe H, Tashiro M, Shidahara M. A systematic performance evaluation of head motion correction techniques for 3 commercial PET scanners using a reproducible experimental acquisition protocol. Annals of Nuclear Medicine. 201907; 33(7):459-470.
Ishii S, Miyajima M, Suenaga H, Sugawara S, Nemoto A, Ukon N, Nambu T, Kubo H, Oriuchi N, Ito H. Detectability of Malignant Lesions by Whole-Body Magnetic Resonance Imaging Using Whole-Body Integrated Positron Emission Tomography/Magnetic Resonance Imaging. Journal of Computer Assisted Tomography. 201907; 43(4):664-670.
Saito M, Aikawa M, Murata T, Ukon N, Komori Y, Haba H, Takács S. Activation cross sections of alpha-induced reactions on natural ytterbium up to 50 MeV. Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms. 201908; 453:15-21.
Murata T, Aikawa M, Saito M, Haba H, Komori Y, Ukon N, Takács S, Ditrói F. Excitation function measurement for zirconium-89 and niobium-90 production using alpha-induced reactions on yttrium-89. Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms. 201911; 458:21-27.
Takács S, Aikawa M, Saito M, Murata T, Ukon N, Komori Y, Haba H. Activation cross sections of alpha particle-induced reactions on natural hafnium up to 50 MeV. Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms. 201911; 459:50-58.
Saito M, Aikawa M, Sakaguchi M, Ukon N, Komori Y, Haba H. Production cross sections of ytterbium and thulium radioisotopes in alpha-induced nuclear reactions on natural erbium. Applied Radiation and Isotopes. 201912; 154:108874.
石井士朗, 渡邊宏剛, 箱崎元晴, 末永博紀, 菅原茂耕, 黒岩大地, 関野啓史, 宮嶋正之, 長谷川靖, 橋本直人, 伊藤 浩. 造影CTで偶然発見された肺血栓塞栓症症例の検討. Japanese Journal of Radiology. 201902; 37(Suppl.):3.
Ukon N, Zhao S, Washiyama K, Oriuchi N, Aoki M, Tan C, Shimoyama S, Nishijima K, Kubo H, Takahashi K, Ito H. Biodistribution and Dosimetry of Free 211At and Meta-[211At]astatobenzylguanidine (MABG) in Normal Mice. Journal of Medical Imaging and Radiation Sciences. 201903; 50(1, Suppl):S18-S19.
Nolen J, Musutapha B, Gott M, de Kruijff R, Song J, Gampa R, Greene J, Zhu S, Rotsch D, Brown MA, Chen CT, Washiyama K, Sampathkumaran U, Winter R. Development of 211At Production via Continuous Extractionof 211Rn. 11th International Symposium on Targeted Alpha-Therapy (TAT11); 20190401; Ottawa, Canada.
Ukon N, Zhao S, Washiyama K, Oriuchi N, Aoki M, Tan C, Nishijima K, Kubo H, Takahashi K, Ito H. Biodistribution and dosimetry of Free and meta-[211At]astatobenzylguanidine (MABG) in normal mice. 11th International Symposium on Targeted Alpha-Therapy (TAT11); 20190401; Ottawa, Canada.
Washiyama K, Oda T, Sasaki S, Aoki M, Guerra Gomez FL, Taniguchi M,Nishijima K, Takahashi K. At-211 production using the CYPRIS MP-30. 11th International Symposium on Targeted Alpha-Therapy (TAT11); 20190401; Ottawa, Canada.
Aoki M, Minegishi K, Nishijima K, Suzuki H, Sasaki S, Washiyama K, Zhao S, Nagatsu K, Zhang M, Takahashi K. Synthesis of [211At]MABG Using Remote-controlled Synthesizer and Quality Evaluation. ISRS 2019; 20190526; Beijing, China.
Yoshinaga K, Zhao S, Washino K, Aoki M, Nishijima K, Shimoyama S, Ukon N, Tan C, Washiyama K, Takahashi K, Ito H, Higashi T. Possibility of 123I-meta-iodobenzylguanidine (123I-MIBG) as companion diagnostic drug for therapeutic alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG). 66th Society of Nuclear Medicine Annual Meeting (SNMMI 2019); 20190622; Anaheim, USA.
Tan C, Zhao S, Ukon N, Shimoyama S, Aoki M, Horita S, Imai R, Maejima Y, Takenoshita S, Shimomura K. Evaluation of the potential of organ glucose metabolism by 18F-FDG accumulation with insulin loading in older mice compared with younger normal mice. 66th Society of Nuclear Medicine Annual Meeting (SNMMI 2019); 20190623; Anaheim, USA.
Takagi H, Zhao S, Muto S, Mine H, Watanabe M, Ozaki Y, Okabe N, Hasegawa T, Shio Y, Aoki M, Tan C, Shimoyama S, Nakamura K, Inano A, Suzuki H. Delta-like 1 homolog(DLK1) expression in non-small-cell lung cancer and the development of radioimmunotherapy targeting DLK1. World Conference on Lung Cancer (WCLC 2019); 20190907; Barcelona, Spain.
Oriuchi N, Zhao S, Aoki M, Tan C, Sugawara S, Nishijima K-I, Shimoyama S, Washiyama K, Takahashi K, Ikezoe T, Ito H. Radiolabeling and biodistribution in the tumor xenograft of 211At-labeled anti-CXCR4 antibody for cancer stem cell targeted alpha-particle therapy. 32nd Annual Congress of the European Association of Nuclear Medicine; 20191012-16; Barcelona, Spain.
Ukon N, Zhao S, Yoshinaga K, Washino K, Aoki M, Nishijima K, Shimoyama S, Tan C, Washiyama K, Oriuchi N, Takahashi K, Higashi T, Ito H. Similarities and differences of dosimetry between meta-[211At]astatobenzylguanidine (211At -MABG) and meta-[123I]iodobenzylguanidine (123I -MIBG) as companion diagnostic drug. 32nd Annual Congress of the European Association of Nuclear Medicine; 20191012-16; Barcelona, Spain.
Washiyama K, Aoki M, Joho T, Ukon N, Nishijima K, Takahashi K, Zhao S, Oriuchi N. An effort to diagnostic and therapeutic nuclear medicine at Fukushima Medical University using two medical cyclotrons. International Symposium on Trends in Radiopharmaceuticals (ISTR 2019); 20191028; Vienna, Austria.
菅原茂耕, 柳沼佑基, 渡邊剛宏, 箱﨑元晴, 末永博紀, 黒岩大地, 関野啓史, 長谷川靖, 石井士朗, 伊藤 浩, 織内 昇. Evaluation the usefulness of the bone SPECT in the Ra223 chloride therapy. 第59回日本核医学会総会; 20191101-03; 松山.
Oriuchi N. Theranostics in Japan and current status of Fukushima Medical University. Theranostics World Congress 2019; 20190301-03; Jeju, Korea.
Ito H, Suenaga H, Sugawara S, Kuroiwa D, Sekino H, Nambu T, Kubo H, Ishii S. Brain perfusion SPECT and FDG-PET studies in dementia. 4th Cognitive Impairment Symposium/13th Asia Oceania Congress of Nuclear Medicine and Biology; 20190509-12; Shanghai, China.
Washiyama K. An effort to diagnostic and therapeutic nuclear medicine at Fukushima Medical University towards the clinical trials. KIRAMS International Symposium on Theranostics: Radioisotopes and Clinical Practice; 20191107; Seoul, South Korea.
Washiyama K. Development and challenges of alpha-emitting radiopharmaceuticals. 2019 The 6th Korean Radiopharmaceutical Society Autumn Symposium; 20191108; Seoul, South Korea.
Washiyama K. Manufacturing and supply of the alpha-emitting radionuclide Astatine-211 in Japan. Technical Meeting on: Production of Alpha Emitters and Radiopharmaceuticals (Ac-225, Bi-213); 20191209-13; Vienna, Austria.
